Background
Fumaric acid esters (
FAE
s) are used to treat psoriasis and are known to cause lymphopenia in roughly 60% of the patients. Much remains to be elucidated about the biological effects of
FAE
s on lymphocytes.
Objective
To evaluate the influence of long‐term
FAE
(Fumaderm
®
) treatment on peripheral blood
CD
4
+
and
CD
8
+
T cells,
CD
19
+
B cells and
CD
56
+
natural killer (
NK
) cells in psoriasis.
Methods
In this single‐centre retrospective observational subcohort study, we obtained leucocyte and lymphocyte subset counts before initiating
FAE
therapy in 371 psoriasis patients (mean age, 47.8 years; 63.3% males) and monitored them during treatment (mean treatment duration, 2.9 years). Multiparametric flow cytometry was used for immunophenotyping.
Results
FAE
s significantly reduced the numbers of
CD
4
+
T,
CD
8
+
T,
CD
19
+
B and
CD
56
+
NK
cells. Among lymphocyte subsets, the mean percentage reduction from baseline was always highest for
CD
8
+
T cells, with a peak of 55.7% after 2 years of therapy. The risk of T‐cell lymphopenia increased significantly with the age of the psoriasis patients at the time that
FAE
therapy was initiated. It was significantly decreased for the combination therapy with methotrexate and folic acid (vitamin B9) supplementation. Supporting evidence was found suggesting that T‐cell lymphopenia enhances the effectiveness of
FAE
therapy.
Conclusions
Monitoring distinct T‐cell subsets rather than just absolute lymphocyte counts may provide more meaningful insights into both the
FAE
treatment safety and efficacy. We therefore suggest optimizing pharmacovigilance by additionally monitoring
CD
4
+
and
CD
8
+
T‐cell counts at regular intervals, especially in patients of middle to older age. Thus, further prospective studies are needed to establish evidence‐based recommendations to guide dermatologists in the management of psoriasis patients who are taking
FAE
s and who develop low absolute T‐cell counts.